1
|
Marani LO, Costa AFO, Kuznetsova V, Faria JTB, Garcia CAB, Scheucher PS, Schiavinato J, Lima ASG, Welner R, Madeira MIA, Gloria ABF, Fagundes EM, Nunes EC, Higashi M, Duarte BK, Pagnano KB, Traina F, Rego EM, Figueiredo-Pontes LL. A EXPRESSÃO DIFERENCIAL DE CÉLULAS PROGENITORAS LEUCÊMICAS DEFINIDAS POR CD99/CD123 ESTÁ ASSOCIADA À MUTAÇÃO FLT3-ITD E RECAÍDA NA LEUCEMIA MIELOIDE AGUDA. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
2
|
Simões LAA, Weinhaüser I, Martins DAP, Pinheiro LHS, Rego EM. PROTEÍNA RECOMBINANTE SLIT1 REDUZ A PROLIFERAÇÃO CELULAR E CAPACIDADE CLONOGÊNICA DE CÉLULAS DE LEUCEMIA MIELOIDE AGUDA. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
3
|
Lima GC, Vicari HP, Nascimento MCD, Lima K, Ferreira MJP, Costa-Lotufo LV, Serra CSM, Rego EM, Machado-Neto JA. A CEFALOCROMINA EXIBE ATIVIDADE CITOTÓXICA EM MODELOS CELULARES DE LEUCEMIA MIELOIDE AGUDA. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
4
|
Silva DLF, Velloso EDRP, Rocha VG, Rego EM, Silva WF. PERFIL DE TOXICIDADE DA PEG-ASPARAGINASE EM PACIENTES ADULTOS COM LEUCEMIA LINFOBLÁSTICA AGUDA. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
5
|
Sousa AMC, Azevedo FS, Zenero PL, Brandão AAGS, Rego EM, Rocha V. HIPOGLICEMIA ASSOCIADA AO USO DE ASPARAGINASE EM TERAPIA DE INDUÇÃO PARA LEUCEMIA LINFOBLÁSTICA AGUDA: RELATO DE CASO. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
6
|
Lima K, Pereira-Martins DA, Miranda LBL, Coelho-Silva JL, Cavaglieri RC, Machado-Neto JA, Rego EM. SYNERGISTIC EFFECTS OF PIP4K2 INHIBITOR AND VENETOCLAX ON APOPTOSIS INDUCTION IN LEUKEMIA CELLS. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
7
|
Costa AFO, Kuznetsova V, Marani LO, Lopes IA, Binelli LS, Scheucher PS, Schiavinato JL, Madeira MIA, Pagnano KBB, Duarte BK, Glória ABF, Rego EM, Traina F, Welner R, Figueiredo-Pontes LL. IMBALANCED ACTIVATING AND INHIBITORY RECEPTORS ON CD56DIM NATURAL KILLER CELLS PREDICTS POOR OUTCOMES IN ACUTE MYELOID LEUKEMIA. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
8
|
Carvalho LV, Lima GG, Melo RCB, Rego EM, Rocha V, Martinez GA, Seguro FS. MIELOMA PLASMABLÁSTICO COM APRESENTAÇÃO ATÍPICA EM ADULTO JOVEM: RELATO DE CASO. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
9
|
Catto LFB, Zanelatto LC, Donaires FS, Carvalho VS, Santana BA, Pinto AL, Fantacini DMC, Traina F, Rego EM, Calado RT. TERRA R-LOOPS ARE INCREASED IN ACUTE MYELOID LEUKEMIA. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
10
|
Silva CA, Pereira J, Rego EM, Rocha V, Silva WF. RISK FACTORS FOR ACUTE KIDNEY INJURY IN OUTPATIENT ADMINISTRATION OF HIGH-DOSE METHOTREXATE IN ADULTS WITHOUT DRUG MONITORING. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
11
|
Marani LO, Garcia CAB, Lopes I, Costa AFO, Madeira MIA, Binelli LS, Schiavinato JL, Scheucher PS, Silva FB, Lima ASG, Fagundes ABFG, Maranhão E, Higashi M, Kerbauy F, Ayoub FL, Duarte BK, Pagnano KB, Traina F, Rego EM, Figueiredo-Pontes LL. ANORMALIDADES 3Q E DESREGULAÇÃO DE EVI1 EM LEUCEMIA MIELOIDE AGUDA: DO DIAGNÓSTICO AO DESFECHO CLÍNICO. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
12
|
Marani LO, Costa AFO, Silva FB, Madeira IA, Scheucher PS, Schiavinato JL, Lima ASG, Dorê A, Pagnano KBB, Duarte BK, Kerbauy F, Feliciano JV, Higashi M, Bittencourt R, Nunes EC, Glória ABF, Fagundes E, Fraga ES, Traina F, Rego EM, Freeman S, Figueiredo-Pontes LL. UNRAVELLING THE HIGH INCIDENCE OF ACUTE MYELOID LEUKEMIA WITH MONOCYTIC BLAST DIFFERENTIATION IN A BRAZILIAN MULTICENTER STUDY. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
13
|
Simões LAA, Weinhaüser I, Martins DAP, Rojas CAO, Bianco TM, Medeiros RCC, Rego EM. TRATAMENTO COM A PROTEÍNA RECOMBINANTE SLIT2 RETARDA O PROCESSO DE LEUCEMOGÊNESE DE LEUCEMIA MIELOIDE AGUDA IN VIVO. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
14
|
Vicari HP, Coelho-Silva JL, Pereira-Martins DA, Lima K, Silva JCL, Costa-Lotufo LV, Rego EM, Traina F, Machado-Neto JA. STATHMIN 1 É ALTAMENTE EXPRESSA E CONTRIBUI PARA A CLONOGENICIDADE EM MODELOS CELULARES DE LEUCEMIA PROMIELOCÍTICA AGUDA. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
15
|
Costa DF, Filiú-Braga LDC, Silva-Carvalho AE, Vasconcelos MCC, Neves FAR, Rego EM, Lucena-Araujo AR, Saldanha-Araújo F. EXPRESSÃO E IMPACTO PROGNÓSTICO DAS DESMETILASES LISINA ESPECÍFICAS 1 (LSD1) E 2 (LSD2) NA LEUCEMIA LINFÓIDE CRÔNICA. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
16
|
Marani LO, Costa AFO, Silva FB, Madeira MIA, Scheucher PS, Schiavinato JL, Lima ASG, Pagnano KBB, Duarte BK, Freeman S, Traina F, Rego EM, Figueiredo-Pontes LL. ABSENT CD33 IN AML PATIENT MIMICS MRD POSITIVE: A SINGLE CASE REPORT. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
17
|
Perruso LL, Silva WF, Velloso EDRP, Rocha V, Rego EM. PATTERNS AND PROGNOSTIC IMPACT OF CNS INFILTRATION IN ADULTS WITH NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
18
|
Lange AP, Almeida LY, Araújo Silva CL, Scheucher PS, Chahud F, Krause A, Bohlander SK, Rego EM. CCAAT/enhancer-binding protein alpha (CEBPA) gene haploinsufficiency does not alter hematopoiesis or induce leukemia in Lck-CALM/AF10 transgenic mice. ACTA ACUST UNITED AC 2019; 52:e8424. [PMID: 31141090 PMCID: PMC6542091 DOI: 10.1590/1414-431x20198424] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Accepted: 03/15/2019] [Indexed: 12/31/2022]
Abstract
Although rare, CALM/AF10 is a chromosomal rearrangement found in immature T-cell acute lymphoblastic leukemia (T-ALL), acute myeloid leukemia, and mixed phenotype acute leukemia of T/myeloid lineages with poor prognosis. Moreover, this translocation is detected in 50% of T-ALL patients with gamma/delta T cell receptor rearrangement, frequently associated with low expression of transcription factor CCAAT/enhancer-binding protein alpha (CEBPA). However, the relevance of CEBPA low expression for CALM/AF10 leukemogenesis has not yet been evaluated. We generated double mutant mice, which express the Lck-CALM/AF10 fusion gene and are haploinsufficient for the Cebpa gene. To characterize the hematopoiesis, we quantified hematopoietic stem cells, myeloid progenitor cells, megakaryocyte-erythrocyte progenitor cells, common myeloid progenitor cells, and granulocyte-macrophage progenitor cells. No significant difference was detected in any of the progenitor subsets. Finally, we tested if Cebpa haploinsufficiency would lead to the expansion of Mac-1+/B220+/c-Kit+ cells proposed as the CALM/AF10 leukemic progenitor. Less than 1% of bone marrow cells expressed Mac-1, B220, and c-Kit with no significant difference between groups. Our results showed that the reduction of Cebpa gene expression in Lck-CALM/AF10 mice did not affect their hematopoiesis or induce leukemia. Our data corroborated previous studies suggesting that the CALM/AF10 leukemia-initiating cells are early progenitors with lymphoid/myeloid differentiating potential.
Collapse
Affiliation(s)
- A P Lange
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Centro de Terapia Celular, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - L Y Almeida
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Centro de Terapia Celular, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - C L Araújo Silva
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Centro de Terapia Celular, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - P S Scheucher
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Centro de Terapia Celular, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - F Chahud
- Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - A Krause
- Laboratório de Análises Clínicas Veterinárias, Universidade Federal de Santa Maria, Santa Maria, RS, Brasil
| | - S K Bohlander
- Leukaemia & Blood Cancer Research Unit, Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand
| | - E M Rego
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Centro de Terapia Celular, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.,Divisão de Hematologia, LIM31, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| |
Collapse
|
19
|
Furtado FM, Scheucher PS, Santana BA, Scatena NF, Calado RT, Rego EM, Matos DM, Falcão RP. Telomere length analysis in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Binet A. ACTA ACUST UNITED AC 2017; 50:e6019. [PMID: 28423121 PMCID: PMC5441285 DOI: 10.1590/1414-431x20176019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Accepted: 02/22/2017] [Indexed: 11/22/2022]
Abstract
Monoclonal B-cell lymphocytosis (MBL) is an asymptomatic clinical entity characterized by the proliferation of monoclonal B cells not meeting the diagnosis criteria for chronic lymphocytic leukemia (CLL). MBL may precede the development of CLL, but the molecular mechanisms responsible for disease progression and evolution are not completely known. Telomeres are usually short in CLL and their attrition may contribute to disease evolution. Here, we determined the telomere lengths of CD5+CD19+ cells in MBL, CLL, and healthy volunteers. Twenty-one CLL patients, 11 subjects with high-count MBL, and 6 with low-count MBL were enrolled. Two hundred and sixty-one healthy volunteers aged 0 to 88 years were studied as controls. After diagnosis confirmation, a flow cytometry CD19+CD5+-based cell sorting was performed for the study groups. Telomere length was determined by qPCR. Telomere length was similar in the 3 study groups but shorter in these groups compared to normal age-matched subjects that had been enrolled in a previous study from our group. These findings suggest that telomere shortening is an early event in CLL leukemogenesis.
Collapse
Affiliation(s)
- F M Furtado
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - P S Scheucher
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - B A Santana
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - N F Scatena
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - R T Calado
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - E M Rego
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - D M Matos
- Hospital Universitário Walter Cantidio, Faculdade de Medicina de Fortaleza, Universidade Federal do Ceará, Fortaleza, CE, Brasil
| | - R P Falcão
- Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| |
Collapse
|
20
|
Rego EM, Pereira Leite J, Bensenor I, Chammas R, Nogueira de Francischi J, da Luz PL. 35 years of the Brazilian Journal of Medical and Biological Research. Braz J Med Biol Res 2017; 50:e6153. [PMID: 28177038 PMCID: PMC5351556 DOI: 10.1590/1414-431x20166153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
Abstract
The authors pay homage to the three founders of the Brazilian Journal of
Medical and Biological Research Profs. Lewis Joel Greene, Sérgio Henrique
Ferreira and Eduardo Moacyr Krieger for their vision and commitment to divulge the
scientific production of developing countries.
Collapse
Affiliation(s)
- E M Rego
- Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - J Pereira Leite
- Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - I Bensenor
- Departamento de Clínica Médica, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| | - R Chammas
- Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| | - J Nogueira de Francischi
- Departamento de Farmacologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil
| | - P L da Luz
- Instituto do Coração, Disciplina de Cardiologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| |
Collapse
|
21
|
Ferreira AK, Santana-Lemos BAA, Rego EM, Filho OMR, Chierice GO, Maria DA. Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects. Br J Cancer 2013; 109:2819-28. [PMID: 24201752 PMCID: PMC3844899 DOI: 10.1038/bjc.2013.510] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 08/05/2013] [Accepted: 08/07/2013] [Indexed: 12/19/2022] Open
Abstract
Background: We recently showed that synthetic phosphoethanolamine reduces tumour growth and inhibits lung metastasis in vivo. Here, we investigated its anti-leukaemia effects using acute promyelocytic leukaemia (APL) as a model. Methods: Cytotoxic effects of Pho-s on leukaemia cells were evaluated by MTT assay. Leukaemic cells obtained from hCG-PML-RARa transgenic mice were transplanted to NOD/SCID mice. After the animals were diagnosed as leukaemic, treatment started with Pho-s using all-trans retinoid acid or daunorubicin as positive control or and saline control. Cell morphology and immunophenotyping were used to detect the undifferentiated blast cells in the spleen, liver and bone marrow. The induction of apoptosis in vitro and in malignant leukaemic clones was evaluated. Results: Synthetic phosphoethanolamine is cytotoxic and induces apoptosis through the mitochondrial pathway in vitro to leukaemia cell lines. In vivo Pho-s exhibits anti-proliferative effects in APL model reducing the number of CD117+ and Gr-1+ immature myeloid cells in the BM, spleen and liver. Synthetic phosphoethanolamine impairs the expansion of malignant clones CD34+/CD117+, CD34+ and Gr-1+ in the BM. In addition, Pho-s induces apoptosis of immature cells in the spleen and liver, a notable effect. Conclusion: Synthetic phosphoethanolamine has anti-leukaemic effects in an APL model by inhibiting malignant clone expansion, suggesting that it is an interesting compound for leukaemia treatment.
Collapse
Affiliation(s)
- A K Ferreira
- 1] Biochemistry and Biophysical Laboratory, Institute Butantan, São Paulo, Brazil [2] Experimental Physiopathology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil
| | | | | | | | | | | |
Collapse
|
22
|
Tamarozzi MB, Soares SG, Sá-Nunes A, Paiva HH, Saggioro FP, Garcia AB, Lucena-Araujo AR, Falcão RP, Bordin JO, Rego EM. Comparative analysis of the pathological events involved in immune and non-immune TRALI models. Vox Sang 2012; 103:309-21. [DOI: 10.1111/j.1423-0410.2012.01613.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
23
|
Brassesco MS, Valera ET, Pezuk JA, Morales AG, Oliveira JC, Umezawa K, Rego EM, Carlotti GC, Scrideli CA, Tone LG, Adachi JI, Suzuki T, Yanagisawa T, Fukuoka K, Mishima K, Wakiya K, Matsutani M, Nishikawa R, Fernandez-L A, Squatrito M, Northcott P, Holland EC, Taylor MD, Nahle Z, Kenney AM, Ashley DM, Muscat A, Gordon L, Rigby L, Birks D, Foreman N, Algar E, Donovan LK, Potter N, Warr T, Pilkington G, Erdreich-Epstein A, Zhou H, Ren X, Davidson TB, Schur M, Ji L, Sposto R, Asgharzadeh S, Hiddingh L, Caretti V, Hulleman E, Kaspers GJL, Vandertop WP, Noske DP, Wurdinger T, Caretti V, Hiddingh L, Lagerweij T, Koken PW, Hulleman E, Vandertop WP, Noske DP, Kaspers GG, Wurdinger T, Bar EE, Schreck K, Eberhart CG, Largaespada DA, Larson JD, Rodriquez FJ, Demer AM, Sarver AL, Dubuc A, Jenkins RB, Dupuy AJ, Copeland NG, Jenkins NA, Taylor MA, Monje M, Freret ME, Beachy PA, Caretti V, Lagerweij T, Jansen MH, Vandertop PW, Noske DP, Kaspers GG, Wurdinger T, Dorris K, Sobo M, Panditharatna E, Liu C, Kim MO, Miles L, Goldman S, Gardner S, Stevenson C, Maugans T, Fouladi M, Drissi R, Fults DW, Mumert M, Pedone CA, Wu X, Northcott PA, Taylor MD, Saratsis AM, Magge S, Rood B, Hill A, Nazarian J, Caretti V, Jansen MH, van Vuurden DG, Hulleman E, Lagerweij T, Bugiani M, Noske DP, Vandertop PW, Wesseling P, Wurdinger T, Kaspers GJ, Gopalakrishnan V, Das C, Gireud M, Taylor P, Singh A, Lee D, Aldape K, Fuller G, Ji L, Fangusaro J, Rajaram V, Goldman S, Eberhart C, Gopalakrishnan V, Taylor P, Fangusaro J, Rajaram V, Goldman S. PEDIATRICS LABORATORY RESEARCH. Neuro Oncol 2011. [DOI: 10.1093/neuonc/nor157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
dos Santos GAS, Abreu e Lima RS, Pestana CR, Lima ASG, Scheucher PS, Thomé CH, Gimenes-Teixeira HL, Santana-Lemos BAA, Lucena-Araujo AR, Rodrigues FP, Nasr R, Uyemura SA, Falcão RP, de Thé H, Pandolfi PP, Curti C, Rego EM. (+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo. Leukemia 2011; 26:451-60. [PMID: 21869839 DOI: 10.1038/leu.2011.216] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The vitamin E derivative (+)α-tocopheryl succinate (α-TOS) exerts pro-apoptotic effects in a wide range of tumors and is well tolerated by normal tissues. Previous studies point to a mitochondrial involvement in the action mechanism; however, the early steps have not been fully elucidated. In a model of acute promyelocytic leukemia (APL) derived from hCG-PML-RARα transgenic mice, we demonstrated that α-TOS is as effective as arsenic trioxide or all-trans retinoic acid, the current gold standards of therapy. We also demonstrated that α-TOS induces an early dissipation of the mitochondrial membrane potential in APL cells and studies with isolated mitochondria revealed that this action may result from the inhibition of mitochondrial respiratory chain complex I. Moreover, α-TOS promoted accumulation of reactive oxygen species hours before mitochondrial cytochrome c release and caspases activation. Therefore, an in vivo antileukemic action and a novel mitochondrial target were revealed for α-TOS, as well as mitochondrial respiratory complex I was highlighted as potential target for anticancer therapy.
Collapse
Affiliation(s)
- G A S dos Santos
- Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Massaro JD, Wiezel CEV, Muniz YCN, Rego EM, de Oliveira LCO, Mendes-Junior CT, Simões AL. Analysis of five polymorphic DNA markers for indirect genetic diagnosis of haemophilia A in the Brazilian population. Haemophilia 2011; 17:e936-43. [PMID: 21649803 DOI: 10.1111/j.1365-2516.2011.02592.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Hemophilia A is an X-linked, inherited, bleeding disorder caused by the partial or total inactivity of the coagulation factor VIII (FVIII). Due to difficulties in the direct recognition of the disease-associated mutation in the F8 gene, indirect diagnosis using polymorphic markers located inside or close to the gene is used as an alternative for determining the segregation of the mutant gene within families and thus for detecting carrier individuals and/or assisting in prenatal diagnosis. This study characterizes the allelic and haplotype frequencies, genetic diversity, population differentiation and linkage disequilibrium of five microsatellites (F8Int1, F8Int13, F8Int22, F8Int25.3 and IKBKG) in samples of healthy individuals from São Paulo, Rio Grande do Sul and Pernambuco and of patients from São Paulo with haemophilia A to determine the degree of informativeness of these microsatellites for diagnostic purposes. The interpopulational diversity parameters highlight the differences among the analyzed population samples. Regional differences in allelic frequencies must be taken into account when conducting indirect diagnosis of haemophilia A. With the exception of IKBKG, all of the microsatellites presented high heterozygosity levels. Using the markers described, diagnosis was possible in 10 of 11 families. The F8Int22, F8Int1, F8Int13, F8Int25.3 and IKBKG microsatellites were informative in seven, six, five and two of the cases, respectively, demonstrating the effectiveness of using these microsatellites in prenatal diagnosis and in carrier identification in the Brazilian population.
Collapse
Affiliation(s)
- J D Massaro
- Departments of GeneticsMedical Clinic, School of Medicine of Ribeirão Preto, University of São Paulo, Brazil
| | | | | | | | | | | | | |
Collapse
|
26
|
Slavov SN, Gimenes Teixeira HL, Rego EM. The role of micro-ribonucleic acids in normal hematopoiesis and leukemic T-lymphogenesis. Braz J Med Biol Res 2010; 43:619-26. [PMID: 20549139 DOI: 10.1590/s0100-879x2010007500057] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2010] [Accepted: 05/25/2010] [Indexed: 01/08/2023] Open
Abstract
Micro-ribonucleic acids (microRNAs) are small molecules containing 20-23 nucleotides. Despite their small size, it is likely that almost every cellular process is regulated by them. Moreover, aberrant microRNA expression has been involved in the development of various diseases, including cancer. Although many data are available about the role of microRNAs in various lymphoproliferative disorders, their impact on the development of acute lymphoblastic leukemia of T-cell progenitors is largely unknown. In this review, we present recent information about how specific microRNAs are expressed and regulated during malignant T-lymphopoiesis and about their role during normal hematopoiesis.
Collapse
Affiliation(s)
- S N Slavov
- Divisão de Hematologia/Oncologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto e Instituto Nacional de Ciência e Tecnologia em Células-Tronco e Terapia Celular, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | | | | |
Collapse
|
27
|
Oliveira LCO, Romano LGM, Prado-Junior BPA, Covas DT, Rego EM, De Santis GC. Outcome of acute myeloid leukemia patients with hyperleukocytosis in Brazil. Med Oncol 2009; 27:1254-9. [PMID: 19937404 DOI: 10.1007/s12032-009-9367-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2009] [Accepted: 11/10/2009] [Indexed: 10/20/2022]
Abstract
Acute myeloid leukemia (AML) with a high white blood cell (WBC) count at presentation has been associated with an increased early mortality rate, usually secondary to leukostasis. However, the value of the WBC count at which there is a high risk of early death (ED) and the efficiency of supportive treatments remain unclear. In this report, a series of 187 consecutive adult patients with AML in our institution was reviewed. The outcome of 40 patients with WBC above 50×10(9) L(-1) (hyperleukocytosis) was compared to 147 patients with a leukocyte count lower than 50×10(9) L(-1). The group with hyperleukocytosis showed a significantly shorter OS (P<0.0001) and a higher rate of ED (P=0.0008). Even when the data from ED patients were removed from analysis, we still detected a shorter OS in patients with hyperleukocytosis (P=0.0049), which suggests that high WBC number influences long-term survival, and not only ED. We also observed higher lactic dehydrogenase (LDH) and serum creatinine levels in the group of patients with hyperleukocytosis (P=0.0003 and 0.0406, respectively). Besides considering all the patients with ED, we could observe higher levels of lactic dehydrogenase, a serum creatinine and nitrogen urea (P=0.0056, P=0.0008 and P<0.0001, respectively). Pulmonary involvement was more frequent in patients with ED (P=0.0277). In conclusion, hyperleukocytosis confers a poorer prognosis in patients with AML.
Collapse
Affiliation(s)
- L C O Oliveira
- Medical School of Ribeirao Preto, University of Sao Paulo, Rua Tenente Catão Roxo, 2501, Ribeirão Preto, SP, 14051-140, Brazil.
| | | | | | | | | | | |
Collapse
|
28
|
Rego EM, Ruggero D, Tribioli C, Cattoretti G, Kogan S, Redner RL, Pandolfi PP. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha. Oncogene 2006; 25:1974-9. [PMID: 16331271 DOI: 10.1038/sj.onc.1209216] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Recurrent chromosomal translocations involving the RAR alpha locus on chromosome 17 are the hallmark of acute promyelocytic leukemia (APL). The RAR alpha gene fuses to variable partners (PML, PLZF, NPM, NuMA and STAT5B: X genes) leading to the expression of APL-specific fusion proteins with identical RAR alpha moieties. To analyse whether the variable X moiety could affect the activity of the fusion protein in vivo, we generated and characterized, on a comparative basis, NPM/RAR alpha transgenic mice (TM) in which the fusion gene is expressed under the control of a human Cathepsin G (hCG) minigene. We compared the features of the leukemia observed in these TM with those in hCG-PML/RAR alpha and hCG-PLZF/RAR alpha TM. In all three transgenic models, leukemia developed after a variably long latency, with variable penetrance. However, the three leukemias displayed distinct cytomorphological features. hCG-NPM/RAR alpha leukemic cells resembled monoblasts. This phenotype contrasts with what was observed in the hCG-PML/RAR alpha TM model in which the leukemic phase was characterized by the proliferation of promyelocytic blasts. Similarly, hCG-PLZF/RAR alpha TM displayed a different phenotype where terminally differentiated myeloid cells predominated. Importantly, the NPM/RAR alpha oncoprotein was found to localize in the nucleolus, unlike PML/RAR alpha and PLZF/RAR alpha, thus possibly interfering with the normal function of NPM. Similarly to what was observed in human APL patients, we found that NPM/RAR alpha and PML/RAR alpha, but not PLZF/RAR alpha leukemia, was responsive to all-trans retinoic acid (ATRA) or As2O3 treatments. Taken together, our results underscore the critical relevance of the X moiety in dictating the biology of the disease and the activity of the APL fusion oncoprotein.
Collapse
Affiliation(s)
- E M Rego
- Cancer Biology and Genetics Program, Department of Pathology, Memorial Sloan-Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
| | | | | | | | | | | | | |
Collapse
|
29
|
Santana BAA, Pintão MC, Abreu e Lima RS, Scheucher PS, Santos GAS, Garcia AB, Falcão RP, Rego EM. Asynchronous expression of myeloid antigens in leukemic cells in a PML/RARalpha transgenic mouse model. Braz J Med Biol Res 2006; 39:615-20. [PMID: 16648899 DOI: 10.1590/s0100-879x2006000500008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Acute promyelocytic leukemia (APL) is characterized by the expansion of blasts that resemble morphologically promyelocytes and harbor a chromosomal translocation involving the retinoic acid receptor alpha (RARalpha) and the promyelocytic leukemia (PML) genes on chromosomes 17 and 15, respectively. The expression of the PML/RARalpha fusion gene is essential for APL genesis. In fact, transgenic mice (TM) expressing PML/RARalpha develop a form of leukemia that mimics the hematological findings of human APL. Leukemia is diagnosed after a long latency (approximately 12 months) during which no hematological abnormality is detected in peripheral blood (pre-leukemic phase). In humans, immunophenotypic analysis of APL blasts revealed distinct features; however, the precise immunophenotype of leukemic cells in the TM model has not been established. Our aim was to characterize the expression of myeloid antigens by leukemic cells from hCG-PML/RARalpha TM. In this study, TM (N = 12) developed leukemia at the mean age of 13.1 months. Morphological analysis of bone marrow revealed an increase of the percentage of immature myeloid cells in leukemic TM compared to pre-leukemic TM and wild-type controls (48.63 +/- 16.68, 10.83 +/- 8.11, 7.4 +/- 5.46%, respectively; P < 0.05). Flow cytometry analysis of bone marrow and spleen from leukemic TM identified the asynchronous co-expression of CD34, CD117, and CD11b. This abnormal phenotype was rarely detected prior to the diagnosis of leukemia and was present at similar frequencies in hematologically normal TM and wild-type controls of different ages. The present results demonstrate that, similarly to human APL, leukemic cells from hCG-PML/RARalpha TM present a specific immunophenotype.
Collapse
MESH Headings
- Animals
- Antigens, CD/genetics
- Antigens, CD/immunology
- Bone Marrow/immunology
- Bone Marrow/pathology
- Cathepsin G
- Cathepsins
- Flow Cytometry
- Genotype
- Immunophenotyping
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Acute/immunology
- Leukemia, Promyelocytic, Acute/genetics
- Leukemia, Promyelocytic, Acute/immunology
- Mice
- Mice, Transgenic
- Oncogene Proteins, Fusion/genetics
- Oncogene Proteins, Fusion/immunology
- Serine Endopeptidases
- Spleen/immunology
- Spleen/pathology
Collapse
Affiliation(s)
- B A A Santana
- Divisão de Hematologia e Centro de Terapia Celular, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Albuquerque LMM, Garcia AB, Mengel JO, Falcão RP, de Castro M, Rego EM. The higher expression of α and β isoforms of the human glucocorticoid receptor in leukemic B-progenitors compared to normal CD10+ BM cells does not correlate with methylprednisolone-induced apoptosis. Leukemia 2004; 18:890-2. [PMID: 14973507 DOI: 10.1038/sj.leu.2403318] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
31
|
Rego EM, Garcia AB, Carneiro JJ, Falcão RP. Immunophenotype of normal and leukemic bone marrow B-precursors in a Brazilian population. A comparative analysis by quantitative fluorescence cytometry. Braz J Med Biol Res 2001; 34:183-94. [PMID: 11175493 DOI: 10.1590/s0100-879x2001000200005] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The distinction between normal and leukemic bone marrow (BM) B-precursors is essential for the diagnosis and treatment monitoring of acute lymphoblastic leukemia (ALL). In order to evaluate the potential use of quantitative fluorescence cytometry (QFC) for this distinction, we studied 21 normal individuals and 40 patients with CD10+ ALL. We characterized the age-related changes of the CD10, CD19, TdT, CD34 and CD79a densities in normal and leukemic BM. Compared to normal adults, the B-precursors from normal children expressed significantly lower values of CD34-specific antibody binding capacity (SABC) (median value of 86.6 vs 160.2 arbitrary units (a.u.) in children and adults, respectively). No significant age-related difference was observed in the expression of the other markers in the normal BM, or in any of the markers in the leukemic BM. Based on the literature, we set the cut-off value for the normal CD10 expression at 45 x 10(3) a.u. for both age groups. For the remaining markers we established the cut-off values based on the minimum-maximum values in the normal BM in each age group. The expression of CD10 was higher than the cut-off in 30 ALL cases and in 18 of them there was a concomitant aberrant expression of other markers. In 9 of the 10 CD10+ ALL with normal CD10 SABC values, the expression of at least one other marker was aberrant. In conclusion, the distinction between normal and leukemic cells by QFC was possible in 38/40 CD10+ ALL cases.
Collapse
Affiliation(s)
- E M Rego
- Fundação Hemocentro de Ribeirão Preto, Centro de Terapia Celular, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.
| | | | | | | |
Collapse
|
32
|
Abstract
Acute promyelocytic leukemia (APL) is characterized by reciprocal chromosomal translocations that always Involve the retinoic acid receptor-alpha (RARalpha) gene on chromosome 17. RARalpha variably fuses to the PML, PLZF, NPM, NuMA, and STAT 5b genes (X genes), leading to the generation of X-RARalpha and RARalpha-X fusion genes. The aberrant X-RARalpha proteins retain the dimerization domains of their parental proteins and therefore can act as dominant negative oncogenic products on both RARalpha/RXR and X pathways. Studies in transgenic mice harboring X-RARalpha and RARalpha-X fusion genes and In mice lacking X genes have helped unravel the molecular mechanisms underlying APL leukemogenesis, which lead to the development of novel therapeutic strategies. Moreover, transgenic mouse models of APL were useful to test in vivo the efficacy of these novel therapeutic approaches as well as of drug combinations such as retinoic acid and As2O3 that were previously known to be effective as single agents in human APL.
Collapse
MESH Headings
- Animals
- Antineoplastic Agents/therapeutic use
- Disease Models, Animal
- Humans
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/etiology
- Leukemia, Promyelocytic, Acute/genetics
- Mice
- Mice, Transgenic
- Oncogene Proteins, Fusion/chemistry
- Oncogene Proteins, Fusion/genetics
Collapse
Affiliation(s)
- E M Rego
- Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | |
Collapse
|
33
|
Abstract
Acute promyelocytic leukemia (APL) is associated with chromosomal translocations that always involve the RARalpha gene, which variably fuses to one of several distinct loci, including PML or PLZF (X genes). Due to the reciprocity of the translocation, X-RARalpha and RARalpha-X fusion proteins coexist in APL blasts. PLZF-RARalpha transgenic mice (TM) develop leukemia that lacks the differentiation block at the promyelocytic stage that characterizes APL. We generated TM expressing RARalpha-PLZF and PLZF-RARalpha in their promyelocytes. RARalpha-PLZF TM do not develop leukemia. However, PLZF-RARalpha/RARalpha-PLZF double TM develop leukemia with classic APL features. We demonstrate that RARalpha-PLZF can interfere with PLZF transcriptional repression and that this is critical for APL pathogenesis, since leukemias in PLZF(-/-)/PLZF-RARalpha mutants and in PLZF-RARalpha/RARalpha-PLZF TM are indistinguishable. Thus, both products of a cancer-associated translocation are crucial in determining the distinctive features of the disease.
Collapse
MESH Headings
- Animals
- Apoptosis/drug effects
- Cell Differentiation/drug effects
- Cell Division/drug effects
- Cell Survival/drug effects
- Cell Transformation, Neoplastic/drug effects
- Cell Transformation, Neoplastic/genetics
- Cell Transformation, Neoplastic/pathology
- DNA-Binding Proteins/antagonists & inhibitors
- DNA-Binding Proteins/genetics
- DNA-Binding Proteins/metabolism
- Gene Expression Regulation, Neoplastic/drug effects
- Hematopoiesis/drug effects
- Humans
- Kruppel-Like Transcription Factors
- Leukemia, Promyelocytic, Acute/genetics
- Leukemia, Promyelocytic, Acute/metabolism
- Leukemia, Promyelocytic, Acute/pathology
- Mice
- Mice, Transgenic
- Mutation/genetics
- Neoplasm Proteins/genetics
- Neoplasm Proteins/metabolism
- Oncogene Proteins, Fusion/genetics
- Oncogene Proteins, Fusion/metabolism
- Promyelocytic Leukemia Zinc Finger Protein
- Repressor Proteins/antagonists & inhibitors
- Repressor Proteins/genetics
- Repressor Proteins/metabolism
- Stem Cells/drug effects
- Stem Cells/metabolism
- Stem Cells/pathology
- Transcription Factors/antagonists & inhibitors
- Transcription Factors/genetics
- Transcription Factors/metabolism
- Transcription, Genetic/drug effects
- Transgenes/genetics
- Translocation, Genetic/genetics
- Tretinoin/pharmacology
Collapse
Affiliation(s)
- L Z He
- Department of Human Genetics and Molecular Biology Program Memorial Sloan-Kettering Cancer Center Sloan-Kettering Institute, New York, NY 10021, USA
| | | | | | | | | | | | | |
Collapse
|
34
|
Rego EM, He LZ, Warrell RP, Wang ZG, Pandolfi PP. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A 2000; 97:10173-8. [PMID: 10954752 PMCID: PMC27786 DOI: 10.1073/pnas.180290497] [Citation(s) in RCA: 149] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Acute promyelocytic leukemia (APL) is associated with chromosomal translocations always involving the RARalpha gene, which variably fuses to one of several distinct loci, including PML or PLZF (X genes) in t(15;17) or t(11;17), respectively. APL in patients harboring t(15;17) responds well to retinoic acid (RA) treatment and chemotherapy, whereas t(11;17) APL responds poorly to both treatments, thus defining a distinct syndrome. Here, we show that RA, As(2)O(3), and RA + As(2)O(3) prolonged survival in either leukemic PML-RARalpha transgenic mice or nude mice transplanted with PML-RARalpha leukemic cells. RA + As(2)O(3) prolonged survival compared with treatment with either drug alone. In contrast, neither in PLZF-RARalpha transgenic mice nor in nude mice transplanted with PLZF-RARalpha cells did any of the three regimens induce complete disease remission. Unexpectedly, therapeutic doses of RA and RA + As(2)O(3) can induce, both in vivo and in vitro, the degradation of either PML-RARalpha or PLZF-RARalpha proteins, suggesting that the maintenance of the leukemic phenotype depends on the continuous presence of the former, but not the latter. Our findings lead to three major conclusions with relevant therapeutic implications: (i) the X-RARalpha oncoprotein directly determines response to treatment and plays a distinct role in the maintenance of the malignant phenotype; (ii) As(2)O(3) and/or As(2)O(3) + RA combination may be beneficial for the treatment of t(15;17) APL but not for t(11;17) APL; and (iii) therapeutic strategies aimed solely at degrading the X-RARalpha oncoprotein may not be effective in t(11;17) APL.
Collapse
MESH Headings
- Animals
- Antineoplastic Agents/therapeutic use
- Apoptosis/drug effects
- Arsenic Trioxide
- Arsenicals/pharmacology
- Arsenicals/therapeutic use
- Cell Differentiation/drug effects
- Chromosomes, Human, Pair 11
- Chromosomes, Human, Pair 15
- Chromosomes, Human, Pair 17
- Humans
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/genetics
- Leukemia, Promyelocytic, Acute/pathology
- Mice
- Mice, Nude
- Mice, Transgenic
- Neoplasm Proteins/drug effects
- Neoplasm Proteins/genetics
- Oncogene Proteins, Fusion/drug effects
- Oncogene Proteins, Fusion/genetics
- Oxides/pharmacology
- Oxides/therapeutic use
- Translocation, Genetic
- Transplantation, Heterologous
- Tretinoin/pharmacology
- Tretinoin/therapeutic use
Collapse
Affiliation(s)
- E M Rego
- Department of Human Genetics, Molecular Biology Program, and Department of Medicine, Molecular Therapeutics Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | |
Collapse
|
35
|
Rego EM, Tone LG, Garcia AB, Falcão RP. CD10 and CD19 fluorescence intensity of B-cell precursors in normal and leukemic bone marrow. Clinical characterization of CD10(+strong) and CD10(+weak) common acute lymphoblastic leukemia. Leuk Res 1999; 23:441-50. [PMID: 10374858 DOI: 10.1016/s0145-2126(98)00190-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
In order to assess the age-related changes in CD10 and CD19 fluorescence intensity (FI) the present study analyzed by flow cytometry 56 sternal biopsies from 'normal' infants, children and adults undergoing cardiac surgery. The CD10(+weak) subset was predominant in all age groups, representing approximately 50% of the bone marrow (BM) lymphoid cells in children younger than 4 years. Both CD10+ subsets significantly decreased with age but their ratio did not differ significantly. Moreover, the intensity of CD10 and CD19 fluorescence in the strong and weak subsets did not vary with age. The CD19 intensity was significantly higher in CD10(+weak) than in CD10(+strong) cells. In addition, we classified as CD10(+weak) or CD10(+strong) the leukemic cells from BM aspirates of 117 patients with common acute lymphoblastic leukemia (cALL) (78 children and 39 adults). A higher frequency of cases expressing the CD19+ CD10(+strong) phenotype was observed both in children and adults. Children of the CD10(+weak) group tended to be older than those of the CD10(+strong) group (median = 7 vs. 4 years, P = 0.07), and presented a significantly higher frequency of splenomegaly (93.7 vs. 55%, P = 0.04), which was massive in about 60% of these cases. Among adults, a significantly higher frequency of cases expressing the CD10(+weak) phenotype was observed in females. No other clinical or biological difference was detected between the two groups either for children or adults. Concerning the treatment outcome, we did not observe significant differences in complete remission rate (CRR) or in disease free survival (DFS) among the 32 children and 28 adults analyzed. Finally, we compared the CD10 and CD19 intensity in normal and leukemic BM. Overexpression of either or both antigens in leukemic cells was observed in 42.4% of the cALL cases. In these cases, using cut off values of 110 afu for the CD10 FI and of 100 afu for the CD19 FI, the detection of leukemic cells was possible at levels of 0.2% based on CD10 analysis, of 0.6% based on CD19, and 0.02% when both antigens were overexpressed. In conclusion, we demonstrated that the heterogeneity of CD10 and CD19 fluorescence intensity is of no clinical relevance in cALL, although its study may be helpful for the diagnosis and the detection of minimal residual disease.
Collapse
Affiliation(s)
- E M Rego
- Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, SP, Brazil
| | | | | | | |
Collapse
|
36
|
|
37
|
Abstract
There is a paucity of information in the literature concerning the age-related changes of the lymphocyte subsets in bone marrow (BM), and the available reports disagree about the characteristics of the population studied and the methods for obtaining, handling, and analyzing the samples. The purpose of the present study was to determine the distribution of lymphoid subsets in the BM from infants, children, and adults by analyzing fragments of sternum obtained during cardiovascular surgery. The samples were studied by flow cytometry employing the whole blood lysis method and excluding from the analysis the contamination of the lymphoid window by erythroid precursors. We observed that in the first 4 years of life the B subset represented more than 65% of all cells in the lymphoid window, most of them (80%) exhibiting the immature phenotype CD19+CD100+. Conversely, the T subset was composed of mature CD4+ or CD8+ cells, with the CD4/CD8 ratio being less than 1 in all age groups. With age there was a progressive decrease in the percentage of B cells and an increase of T cells, reaching similar proportions in the BM from adults (33.6% and 34.8%, respectively). Furthermore, the percentage of CD10+ cells in the B subset decreased independently, whereas the CD20 expression increased. The percentage of NK cells did not change with age.
Collapse
Affiliation(s)
- E M Rego
- Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, Brazil.
| | | | | | | |
Collapse
|
38
|
Abstract
The distribution of the acute lymphoblastic leukemia (ALL) subsets in 225 consecutive Brazilian patients was determined by an immunophenotypic study with an extensive panel of monoclonal antibodies. All subsets were detected and their relative frequencies were similar to those described in developed countries, except for the B-mature subset which had a higher frequency, especially in adults. Associated myeloid markers were expressed by 11% of the ALL and CD10 by 15.9% of T-ALL cases. Besides, the incidence rates determined for the region of Ribeirão Preto showed that the overall incidence of ALL was 12.5 cases/10(6) people years (PY) (5 cases/10(6) PY in non-Whites versus 14 cases/10(6) PY in Whites); the incidence of childhood ALL was 25.5 cases/10(6) PY (8.1 versus 29.8 cases/10(6) PY in non-Whites and Whites, respectively) and the incidence of ALL in adults was 6.2 cases/10(6) PY (5.5 versus 6.1 cases/10(6) Py in non-Whites and Whites, respectively). The significantly lower incidence rate of ALL in non-White children was associated with a selective deficit of the common subtype and a lack of the typical age peak of incidence in this group. The ALL features demonstrated here in Brazilian non-White children resemble those described in the American non-Whites before the seventies and those in British and American Whites at the beginning of the century.
Collapse
Affiliation(s)
- E M Rego
- Department of Internal Medicine, School of Medicine, Ribeirão Preto, University of São Paulo, Brazil
| | | | | | | |
Collapse
|
39
|
da Fonseca LM, Brunetti IL, Rego EM, Garcia AB, Cilento G, Falcão RP. Characterization of myeloid or lymphoid acute leukemia by a chemiluminescence assay. Comparison with immunocytochemistry using an antimyeloperoxidase antibody. Acta Haematol 1993; 90:19-24. [PMID: 8237269 DOI: 10.1159/000204367] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
A simple and sensitive chemiluminescence assay for the demonstration of the activity of intracellular myeloperoxidase (MPO) is described, which is useful for the distinction between myeloid and lymphoid commitment in blasts from acute leukemia patients. When the cut-off point was settled at 13 mV of chemiluminescence all cases of acute myeloid leukemia (AML) were distinguished from those of acute lymphoid leukemia. In addition, this technique was able to demonstrate MPO activity in AML poorly differentiated (FAB-M0) which usually does not stain for MPO in classical cytochemistry preparations and could be negative also by immunocytochemistry with anti-MPO monoclonal antibody. Therefore the method here described presented a higher sensitivity than the immunocytochemistry procedure with anti-MPO.
Collapse
Affiliation(s)
- L M da Fonseca
- Department of Clinical Analysis, Faculty of Pharmaceutical Sciences, UNESP, Araraquara, Brazil
| | | | | | | | | | | |
Collapse
|
40
|
Rego EM, Corrado AP, Prado WA. Antinociception induced by intracerebroventricular or intrathecal administration of gentamicin in rats. Gen Pharmacol 1992; 23:481-5. [PMID: 1511855 DOI: 10.1016/0306-3623(92)90115-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
1. The intrathecal (i.t.) administration of gentamicin (AD50 = 3.98 micrograms) produced marked and dose-dependent antinociception in rats, as assessed by the tail-flick test. A weaker effect was obtained following intracerebroventricular drug administration (AD50 = 50.12 micrograms). 2. A transitory but dose-dependent antagonism of the effect of i.t. gentamicin was obtained following i.t. administration of calcium chloride (4 and 8 micrograms). 3. The magnitude and duration of morphine antinociception (5 micrograms, i.t.) were enhanced by the previous (intraperitoneal) i.p. or i.t. administration of gentamicin. 4. These results indicate that gentamicin-induced antinociception may depend on its calcium-antagonist property and involves drug diffusion to a spinal site of action.
Collapse
Affiliation(s)
- E M Rego
- Department of Pharmacology, Faculty of Medicine of Ribeirão Preto, SP, Brazil
| | | | | |
Collapse
|
41
|
Abstract
Intraperitoneal administration of gentamicin sulfate (5-800 micrograms/kg), but not gentamicin base (23-92 micrograms/kg) produced antinociception in rats and mice, as assessed by the tail-flick, carrageenan-induced articular incapacity tests, and hot-plate tests. The AD50 s in rats (tail-flick test) and mice (hot-plate test) were 11.48 and 147.9 micrograms/kg, respectively, but doses of 200-800 micrograms/kg were required to reduce the hyperalgesia induced in rats by carrageenan. In both species, bell-shaped dose-response curves were obtained, indicating that high doses of gentamicin had little or no effect. Non-effective doses of gentamicin failed to produce a significant increase in morphine antinociception in either rodent species. The possible involvement of N-type voltage-sensitive Ca2+ channels in the mechanism of antinociception induced by gentamicin is considered.
Collapse
Affiliation(s)
- W A Prado
- Department of Pharmacology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, 14049 Ribeirão Preto, SP, Brazil
| | | | | | | |
Collapse
|